论文部分内容阅读
目的：了解促肝细胞生长素对重症肝炎患者血清ＩＬ－６、ＩＬ－８的影响。方法：采用双抗体夹心ＥＩＳＡ法观察７８例各型重症肝炎经ＰＨＧＦ治疗后血清ＩＬ－６、ＩＬ－８的动态改变。结果：重症肝炎患者血清ＩＬ－６、ＩＬ－８水平较对照组明显升高，且亚急、慢性重症肝炎ＩＬ－６水平明显高于急性重症肝炎，乙型肝炎病毒感染者ＩＬ－６、ＩＬ－８水平明显高于甲、戊型病毒感染者。ＰＨＧＦ治疗后各型重症肝炎死亡率明显下降，其血清胆红素水平与ＩＬ－６、ＩＬ－８水平的下降呈明显正相关，且下降时间早、幅度大，治疗８周后血清ＩＬ－６、ＩＬ－８水平较对照治疗组明显下降。结论：监测ＩＬ－６、ＩＬ－８水平能反映重症肝炎的肝损伤程度及判定预后；ＰＨＧＦ能改善重症肝炎的免疫功能紊乱，减轻肝坏死和炎症细胞浸润。
Objective: To investigate the effect of hepatocyte growth-promoting hormone on serum IL-6 and IL-8 in patients with severe hepatitis. Methods: The dynamic change of serum IL-6 and IL-8 in 78 severe hepatitis patients treated with PHGF was observed by double-antibody sandwich ELISA. Results: Serum levels of IL-6 and IL-8 in patients with severe hepatitis were significantly higher than those in control group, and the levels of IL-6 in sub-acute and chronic severe hepatitis were significantly higher than those in acute severe hepatitis. The levels of IL-6 and IL- -8 levels were significantly higher than A, E virus infection. After the treatment of PHGF, the death rate of various types of severe hepatitis decreased significantly. The level of serum bilirubin was positively correlated with the decrease of IL-6 and IL-8 levels, and the decline time was earlier and larger. After 8 weeks of treatment, the serum IL-6 , IL-8 levels decreased significantly compared with the control group. CONCLUSION: Monitoring the levels of IL-6 and IL-8 can reflect the degree of liver injury and prognosis in patients with severe hepatitis. PHGF can improve the immune function of severe hepatitis and reduce the necrosis of liver and the infiltration of inflammatory cells.